Carregant...

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Oyajobi, Babatunde O., Garrett, I. Ross, Gupta, Anjana, Flores, Alda, Esparza, Javier, Muñoz, Steve, Zhao, Ming, Mundy, Gregory R.
Format: Artigo
Idioma:Inglês
Publicat: 2007
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482356/
https://ncbi.nlm.nih.gov/pubmed/17910634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2007.06829.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!